目的 探討復方腎炎片聯(lián)合來氟米特和潑尼松治療狼瘡性腎炎（LN）的臨床療效。方法 選取2015年1月-2015年6月在?？谑腥嗣襻t(yī)院接受治療的LN患者84例，根據(jù)治療方案的差別分為對照組和治療組，每組各42例。對照組口服醋酸潑尼松片，1 mg/（kg·d），2個月后逐漸減至10 mg/d；同時口服來氟米特片，20 mg/d。治療組在對照基礎上口服復方腎炎片，3片/次，3次/d。兩組患者均連續(xù)治療6個月。觀察兩組的臨床療效，比較治療前后兩組患者各項血肌酐（Scr）、24 h尿蛋白定量（24 h Upro）、紅細胞（RBC）、β₂-微球蛋白（β₂-MG）、血漿白蛋白（Alb）、紅細胞沉降率（ESR）和補體C3情況以及SLEDAI積分變化。結果 治療后，對照組和治療組的總有效率分別為71.43%、90.48%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者Scr、24 h Upro、RBC計數(shù)、β₂-MG、ESR水平均較治療前顯著降低，Alb和C3水平顯著升高，同組治療前后差異具有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標的改善程度優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者SLEDAI積分均明顯降低（P<0.05），治療組患者SLEDAI積分比對照組降低更顯著（P<0.05）。對照組和治療組的不良反應發(fā)生率分別為26.19%、9.52%，兩組比較差異有統(tǒng)計學意義（P<0.05）。結論 復方腎炎片聯(lián)合來氟米特、潑尼松治療LN效果顯著，可明顯提高臨床緩解率，且不良反應發(fā)生率低，具有一定的臨床推廣應用價值。

Objective To investigate the clinical effect of Compound Shenyan Tablets combined with leflunomide and prednisone in treatment of lupus nephritis. Methods Patients (84 cases) with lupus nephritis in Haikou People's Hospital from January 2015 to June 2015 were divided into control and treatment groups according to different treatments, and each group had 42 cases. The patients in the control group were po administered with Prednisone Acetate Tablets, 1 mg/(kg·d), the dosage was gradually reduced to 10 mg/d after two months. And they were po administered with Leflunomide Tablets, 20 mg/d. The patients in the treatment group were po administered with Compound Shenyan Tablets on the basis of the control group, 3 tablets/time, three times daily. The patients in two groups were treated for six months. After treatment, the efficacy was evaluated, and the changes of Scr, 24 h Upro, RBC, β₂-MG, Alb, ESR, and C3 levels, and SLEDAI scores in two groups before and after treatment were compared. Results After treatment, the efficacy in the treatment group (90.48%) was higher than that (71.43%) of the control group, and there were differences between two groups (P<0.05). After treatment, levels of Scr, 24 h Upro, RBC, β₂-MG, and ESR in two groups were significantly decreased, but levels of Alb and C3 were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, SLEDAI scores in two groups were significantly decreased (P<0.05), which were significantly better in the treatment group than those in the control group (P<0.05). The incidence of adverse reactions in the control and treatment groups were 26.19% and 9.52%, respectively, and there was difference between two groups (P<0.05). Conclusion Compound Shenyan Tablets combined with leflunomide and prednisone has clinical curative effect in treatment of lupus nephritis, can significantly improve the clinical remission rate with a low incidence of adverse reactions, which has a certain clinical application value.